Precision Medicine Advances in Thyroid Cancer: Translating Clinical Evidence into Practice

Precision Medicine Advances in Thyroid Cancer: Translating Clinical Evidence into Practice is organized by Springer Healthcare IME

Overview:
With the continued discovery of new genomic targets in thyroid cancer, identifying molecular biomarkers is crucial in determining the best targeted treatment options. Increase your knowledge of advances in molecular testing and targeted therapies for advanced thyroid cancer in this expert-led program.

The discovery of oncogenic driver mutations and the development of targeted therapies have revolutionized treatment for many cancers, including thyroid cancer, in which molecular-targeted therapy has provided new options for previously untreatable tumor types. This expert-led program will discuss recent advances in molecular testing and targeted treatments for advanced thyroid cancer, with a focus on metastatic medullary thyroid cancer (MTC) and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

An overview of recent drug approvals and guideline recommendations will be provided, to explain how precision medicine advances can be translated into clinical practice. With increased confidence in the new targeted treatment options, you will be able to apply precision medicine approaches in clinical practice to achieve optimal personalized care for your patients.

This program is suitable for global oncologists, endocrinologists, pathologists, and other healthcare professionals involved in the diagnosis, treatment, and follow-up of patients with thyroid cancer.

Program features
Webcast: In this 50-minute symposium, our experts Laura Fugazzola, Lori J Wirth and Rossella Elisei discuss precision medicine approaches for the treatment of advanced thyroid cancer and consider how clinical evidence can be translated into practice.

Vodcasts: Watch our experts, Laura Fugazzola, Lori J Wirth and Rossella Elisei, explain the latest advances in precision medicine for advanced thyroid cancer in a series of five short vodcasts.

eLearning Modules: In these interactive case study modules, experts Laura Fugazzola and Lori J Wirth will cover the best practices for molecular testing and targeted therapy for advanced radioactive iodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer.

Learning Objectives:

After participating in the program activities and/or studying its content, learners will be able to:

• Identify patients with tumor types that may harbor actionable molecular alterations and apply appropriate methods to detect these biomarkers in practice
• Debate recent advances in thyroid cancer management, including the latest treatments available for different types of thyroid cancer and updates to clinical practice guidelines
• Integrate new precision medicine approaches into their clinical practice

This program has been funded by a grant for Independent Medical Education provided by Lilly. The Company has had no input to the content.